# OnCo record nct06081244 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06081244/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06081244", "NCT06081244" ;
  schema:name "NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)"@en ;
  schema:alternateName "ADAPT-TN-III"@en ;
  schema:description "A phase 3 trial of sacituzumab govitecan and pembrolizumab in triple-negative breast cancer, run by Women's Cancer Study Group GmbH, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06081244/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06081244> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest", "tnbc-deep-dive" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/tnbc-early/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/sacituzumab-govitecan/>, <https://onco.cc/drugs/pembrolizumab/> .